NCT04676555 - Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

October 21, 2021

Study Completion Date

October 21, 2021

Conditions

Relapsing Forms of Multiple Sclerosis

Interventions

DRUG

Ocrelizumab

There is no treatment allocation. Patients administered Ocrelizumab by prescription that have started before inclusion of the patient into the study will be enrolled.

DRUG

Ofatumumab

There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.

Trial Locations (2)

3050

Novartis Investigative Site, Parkville

21093

Novartis Investigative Site, Lutherville